Phathom. PHARMACEUTICALS CHANGING THE LANDSCAPE IN GI

Going beyond to advance treatments for patients with acid-related disorders

CORPORATE OVERVIEW

November 2022

Safe harbor statement

This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, prospective products, product approvals, research and development costs, timing and likelihood of success, plans and objectives of management for future operations, and future results of current and anticipated products, are forward-looking statements.

In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other similar expressions. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks, uncertainties and other factors include, without limitation: the inherent risks of clinical development of vonoprazan; our dependence on third parties in connection with product manufacturing, research and preclinical and clinical testing; regulatory developments in the United States and foreign countries; our ability to obtain regulatory approvals for and successfully launch and commercialize products containing vonoprazan; our ability to successfully address the formation of nitrosamine impurities in commercial batches of vonoprazan drug product and gain FDA approval of any such resolution; unexpected adverse side effects or inadequate efficacy of vonoprazan that may limit its development, regulatory approval and/or commercialization, or may result in recalls or product ilability claims; our ability to obtain and maintain intellectual property protection for vonoprazan; our ability to comply with our license agreement with Takeda; our ability to maintain undisrupted business operations due to the ongoing COVID-19 pandemic, including delaying or otherwise disrupting clinical trials, manufacturing and supply chain, and launch and commercialization efforts; our ability to achieve and maintain adequate levels of coverage and reimbursement for vonoprazan; the availability of additional funds under our revenue interest financing agreement and Exchange Commission (SEC), including our Annual Report on Form 10-K

This presentation also contains estimates and other statistical data made by independent parties and by us relating to market size and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions, and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk.



Pharmaceuticals

Going beyond

to advance treatments for patients with acid related disorders

Locations HQ: Florham Park, NJ Buffalo Grove, IL

FDA APPROVED PRODUCTS Vonoprazan-based *H. pylori* regimens Formed In 2019 Listed on NASDAQ: PHAT



Vonoprazan:

First innovative acid-suppressant from a new drug class in the US in over 30 years

Belongs to a novel class of therapies called PCABs (Potassium Competitive Acid Blockers)

Erosive esophagitis (EE) and *H. pylori* US launch targeted for 1Q 2023

- Potential to displace PPIs
- Large market opportunity
- NCE exclusivity until 2032 under GAIN Act Extension

US / Europe / Canada rights licensed from

Takeda

Approved in **16 COUNTRIES** across Asia & Latin America


~\$850M

Annual net sales in Japan. Achieving market leadership of 43% revenue-based market share¹



¹ US dollars based on conversion rate of 0.0090 dollars to one yen. Sales for the twelve-months ended Dec. 31, 2021


Commercial success of acid suppression treatments





Vonoprazan demonstrated improved acid control versus PREVACID (lansoprazole)

RAPID, POTENT, DURABLE ACID SUPPRESSION*




Mean gastric pH profiles for vonoprazan were higher than PREVACID (lansoprazole) on both Days 1 and 7

*VONO-103: Mean 0-24 hour gastric pH profiles; study evaluating the PK, PD, safety and tolerability of vonoprazan in comparison to PREVACID (lansoprazole) in 41 healthy adult subjects ¹ Shah SC et al. Gastroenterology. 2021;160:1831–1841



Mechanistic differences between PPIs and PCABs



Phathom pipeline: promising late-stage opportunities for unmet GI needs

		Target indications	Phase 1 ¹	Phase 2 ¹	Phase 3	Milestones	Approved
H. pylori	Vonoprazan + antibiotics	VOQUEZNA TriplePak. vonoprazan amoxicillin clarithromycin tablets 200mg capsules 500mg tablets 500mg			PHalcocky A research study for 14 pyter / Artyce	US launch targeted in 1Q 2023	FDA approved May 2022
H. P.		VOQUEZNA DualPak. Vonoprazan tablets zoma capsules 500mg					
(Erosive)		Healing of Erosive esophagitis (EE)			pHalcon	Positive Phase 3 results	
	Vonoprazan	and relief of heartburn Maintenance of healing			A research study for Evolve Exophonics	<i>PDUFA action date Jan 11, 2023</i>	
GERD		of EE and relief of heartburn				US launch targeted in Q1 2023	
ive)	Vonoprazan (daily dosing)	Daily dosing treatment of heartburn associated with NERD		PHalcon unter		Last patient enrolled Oct 2022	
n-erosive)						<i>Topline results expected in Q1 2023</i>	
GERD (No	Vonoprazan (on-demand)	On-demand treatment of heartburn associated with Non-erosive reflux disease (NERD)		pHalcon atmet		Positive Phase 2 results	
						Phase 3 trial design underway	
EoE	Vonoprazan	Treatment of eosinophilic esophagitis (EoE) for adult & pediatric use				Phase 2 trial design underway	


Phathom

PHARMACEUTICALS

Phathom has development and commercialization rights to vonoprazan in the United States, Europe, and Canada

¹Phase 1 and 2 studies supporting application for healing of Erosive Esophagitis, maintenance of healing of Erosive Esophagitis, and *H. pylori* treatment conducted by Takeda

Vonoprazan vision builds on each indication with the potential to transform the landscape of acid-related disorders





Superior efficacy results from PHALCON-EE phase 3 study

If approved, vonoprazan would be the first product with superiority data in maintenance of EE healing over a PPI, further differentiating the product from PPIs



Healing of EE and relief of heartburn

1


2

Maintenance of EE healing and relief of heartburn

Superiority data provides potential clinical differentiation from a commonly prescribed proton pump inhibitor (PPI)



Superior healing at 2 weeks in patients with moderate-to-severe disease^{1,2}




Superior maintenance of healing in patients with moderate-to-severe disease²



¹Healing rate in all patients was also numerically greater at week 2 but could not be formally tested based on pre-specified testing hierarchy ²Moderate-to-severe EE classified as LA Class Grade C/D


PHALCON-EE phase 3 met primary and key secondary healing endpoints





^nominal p-value presented, superiority comparison, not formally tested based on pre-specified testing hierarchy *p-value for both primary non-inferiority endpoint and unadjusted p-value for exploratory superiority comparison #p-value for pre-specified secondary endpoint superiority comparison

PHALCON-EE phase 3 met all maintenance of healing endpoints





*p-value for primary endpoint non-inferiority comparison #p-value for pre-specified secondary endpoint superiority comparison

Summary of PHALCON-EE phase 3 safety data

Overall, the safety results observed in PHALCON-EE were consistent with those observed in prior clinical studies of vonoprazan

Healing Phase

Most Common Adverse Events

% (n)	Vonoprazan 20 mg	Lansoprazole 30 mg	
Diarrhea	2.1% (11)	2.5% (13)	

Maintenance Phase

Most Common Adverse Events (≥ 5%)

% (n)	Vonoprazan 20 mg	Vonoprazan 10 mg	Lansoprazole 15 mg
Abdominal Pain	5.4% (16)	4.1% (12)	2.4% (7)
Gastritis	2.7% (8)	6.4% (19)	2.7% (8)
COVID-19	10.1% (30)	6.1% (18)	6.7% (20)

Both Phases


Serious Adverse Events (>1 patient)

	Vonoprazan	Vonoprazan	Lansoprazole
	20 mg	10 mg	15 mg
COVID-19* (n)	5	2	0




*No COVID-19 SAEs were deemed related to the study drug by the investigator | Safety Set: All subjects who received at least one dose of study medication

Unique development strategy for treatment of NERD





PHALCON-NERD-201 phase 2 trial design (completed)



¹ Dosing initiated at onset of a heartburn episode; rescue antacid medication allowed after 3 hours of taking test medication


²Patients must meet study drug and diary completion compliance requirements

³ Primary endpoint for NERD phase 2 trial is complete heartburn relief at 3 hours that is sustained for 24 hours. Primary endpoint for phase 3 trial will be based on NERD phase 2 results and subsequent FDA discussions



PHALCON-NERD-201 met the primary endpoint for all doses

% of evaluable episodes* with complete and sustained heartburn relief within 3 hours^




Evaluable episode – nearburn episode for which subject completes a minimum of one timed assessment.

^Complete relief: Full symptom relief with no rescue antacid taken (must be achieved within 3 hours of study drug); Sustained relief: No further episodes recorded within following 24 hours



Each vonoprazan dose significantly separated from placebo by 1 hour in PHALCON-NERD-201



#denotes p < 0.01 statistically significant difference from placebo


^Evaluable episode = heartburn episode for which subject completes a minimum of one timed assessment

^^Complete relief: Full symptom relief with no rescue antacid taken (must be achieved within 3 hours of study drug); Sustained relief: No further episodes recorded within following 24 hours




PHALCON-NERD-301 phase 3 daily dosing trial design

Topline primary endpoint data expected in 1Q 2023




HARMACEUTICAL

We believe vonoprazan's pharmacologic profile is well-suited for both NERD daily and on-demand dosing



GERD represents a large U.S. market with high unmet need



¹ Vaezi MF, Brunton S, Mark Fendrick A, et al. Patient journey in erosive esophagitis: real-world perspectives from US physicians and patients. BMJ Open Gastroenterology 2022;9:e000941. doi: 10.1136/bmjgast-2022-000941
² El-Serag HB, Sweet S, Winchester CC, Dent J. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2014;63(6):871-880. doi:10.1136/gutjnl-2012-304269
³ Machicado J.D., Greer J.B., Yadav D. (2020) Epidemiology of Gastrointestinal Diseases. In: Pitchumoni C., Dharmarajan T. (eds) Geriatric Gastroenterology. Springer, Cham. https://doi.org/10.1007/978-3-319-90761-1_7-1
⁴ U.S. Census Bureau, U.S. and World Population Clock. Accessed May 2022, https://www.census.gov/popclock.




19

* Based on Phathom market research.

Typical GERD patient journey highlights current dissatisfaction

EE & NERD patient journeys are similar; both include multiple lines of PPI therapy






* Visual a summary of patient journey qualitative market research, May 2020
*Symphony APLD claims analysis

HCPs see vonoprazan as differentiated from PPIs

HCP's perception of PPI potency falls drastically after seeing vonoprazan clinical data




HCPs agree vonoprazan is differentiated vs. existing treatments by having...¹




PHARMACEUTICALS

¹ EE Demand Study / Jan 2022 / n=301 (151 GI; 100 PCP; 50 APP) ² HP Messaging / November 2021 / n=222 (111 GI; 83 PCP; 28 APP)

Physician research indicates high intention to prescribe vonoprazan








¹EE Demand Study / Jan 2022 / n=301 (151 GI; 100 PCP; 50 APP) ²HP Demand Study / July 2021 / n=242 (100 GI; 102 PCP; 40 APP)


High volume HCPs to be reached by salesforce coupled with broad and aggressive communication campaign





Source: Internal analysis of IQVIA Xponent Retail PPI Rx data (2020) in conjunction with Symphony Health claims analysis (2017-2019)

Vonoprazan access and pricing strategy intended to achieve broad access



PHARMACEUTICALS

¹ Vonoprazan is taken BID during the 14 day regimen (i.e., 28 vonoprazan pills per therapy).

Significant opportunity and attractive commercial dynamics exist for blockbuster potential



Large Unmet Needs

Large population & high level of dissatisfaction

Differentiat

Differentiated Profile

Novel MOA & clinical differentiation

On the second se

Physician Attractiveness

Strong physician interest & concentrated high prescribers




No Branded Competition

No branded competition & share of voice ownership



H. pylori & Erosive Esophagitis U.S. launch targeted for Q1 2023



Displace PPIs to become the #1 prescribed acid suppressant



Financial highlights (as of September 30, 2022)

\$196.8M cash and cash equivalents

Up to **\$200M** remaining in royalty financing¹ + **\$100M** available via term loan²

~42M shares outstanding

Cash, cash equivalents, and other anticipated capital expected to provide **runway through 2024** including full funding of the *H. pylori* and Erosive Esophagitis launches,

and future anticipated development programs³

¹ The total royalty interest financing agreement accounts for up to \$300M. Phathom recently announced placement of the remaining \$40M under the terms set forth in the original agreement. To date, Phathom has received \$100M under the royalty interest financing agreement which is included in cash and cash equivalents.

² All tranche terms have been satisfied, allowing Phathom to draw down remaining funds strategically, at any time.

³ Assumes satisfaction of all royalty financing terms, full drawdown under remaining term loan, and anticipated future product sales, pursuant to management operating plan.



Expected near-term milestones

		Target indications		2022	2023
H. pylori	Vonoprazan + antibiotics	VOQUEZNA TriplePak. Vonoprazan amoxicillin clarithromycin tablets 500mg Clarithromycin tablet	-	Approved	Planned 1Q 2023 US launch
GERD (Erosive)	Vonoprazan	Healing of Erosive esophagitis (EE) and relief of heartburn Maintenance of healing of EE and relief of heartburn		NDA submission	PDUFA Date: January 11, 2023 Planned 1Q 2023 US launch
(Non-erosive)	Vonoprazan (daily dosing)	Daily dosing treatment of heartburn associated with NERD		Positive topline Ph 2 results for NERD on-demand trial	Topline primary endpoint results from Ph 3 NERD daily dosing trial 1Q 2023
GERD (No	Vonoprazan (on-demand)	On-demand treatment of heartburn associated with Non-erosive reflux disease (NERD)			NERD daily dosing sNDA submission 2H 2023
ЕоЕ	Vonoprazan	Treatment of eosinophilic esophagitis (EoE) for adult & pediatric use	On	going Ph 2 design	Planned trial initiation 2H 2023
		cialization rights to vonoprazan in the United States, Europe, and cation for healing of Erosive Esophagitis, maintenance of healing		s, and <i>H. pylori</i> treatment conducted by Takeda	Phathom

PHARMACEUTICALS

Appendix: Phathom's Clinical Trial Results



pHalcon-HP


Phase 3 trial for *H. pylori* infection



pHalcon-HP phase 3 study design



4 Weeks Post-Treatment




14 Day

Diagnosis of infection and test of cure confirmed by 13C-urea breath test Vonoprazan dual therapy = vonoprazan 20 mg BID + amoxicillin 1 g TID Vonoprazan triple therapy = vonoprazan 20 mg BID + amoxicillin 1 g BID + clarithromycin 500 mg BID Lansoprazole triple therapy = lansoprazole 30 mg BID + amoxicillin 1 g BID + clarithromycin 500 mg BID



PHALCON-HP met primary endpoints


Eradication rates (%) among patients without clarithromycin- or amoxicillin-resistant strains







¹ Not adjusted for multiple comparisons

Both vonoprazan-based therapies met superiority for secondary endpoints







Safety profile

vonoprazan-based regimens generally well tolerated; comparable to lansoprazole triple therapy

% (n) with adverse event	Vonoprazan triple therapy (n=346)	Vonoprazan dual therapy (n=348)	Lansoprazole triple therapy (n=345)
Diarrhea	4.0% (14)	5.2% (18)	9.6% (33)
Nausea	1.7% (6)	1.7% (6)	2.6% (9)
Dysgeusia	4.3% (15)	0.6% (2)	6.1% (21)
Headache	2.6% (9)	1.4% (5)	1.4% (5)
Vaginal infection	2.3% (8)	0.9% (3)	0.3% (1)

Most frequent (>2.0%) adverse events in pHalcon-HP subjects

Safety Set: All subjects who received at least one dose of study medication



pHalcon-EE

Phase 3 trial for Erosive Esophagitis (EE)






PHALCON-EE phase 3 study design

US/Europe study in Erosive Esophagitis








¹ Represents modified intent to treat (mITT) population

PHALCON-EE phase 3 met primary and key secondary endpoints



^{*}Healing phase primary endpoint, exploratory superiority comparison, nominal p<0.0001

[^]Maintenance phase primary endpoint, prespecified secondary superiority comparison: vonoprazan 20 mg: p=0.0136; vonoprazan 10 mg p=0.0436

*Sustained resolution of heartburn is defined as seven (7) consecutive days without heartburn symptoms. For this test to be satisfied a patient must commence the seven consecutive day period on either

37 day 1, 2 or 3 and last, respectively, up to day 7, day 8 or day 9.

Phathom. PHARMACEUTICALS


pHalcon-NERD-201

Phase 2 trial for non-erosive reflux disease (NERD)



PHALCON-NERD-201 met the key secondary endpoint with all doses resulting in more complete relief of heartburn episodes compared with placebo

% of evaluable episodes^{*} with complete heartburn relief within 3 hours[^] (with or without 24-hour sustained relief)



PHARMACEUTICALS

PHALCON-NERD-201 safety data

The safety data for all vonoprazan arms were comparable to placebo and consistent with what was reported in previous studies

Daily dosing treatment phase Vonoprazan 20 mg QD

- Most commonly reported events (> 1% of subjects)
 - Abdominal distension 1.3%
 - Diarrhea 1.5%
 - Nausea 1.3%
- 4 SAEs
 - 1 study drug related SAE (anaphylactic reaction)

On-demand treatment phase

	Placebo (n=52)	Vonoprazan 10 mg (n=52)	Vonoprazan 20 mg (n=52)	Vonoprazan 40 mg (n=51)
% (n) of subjects with at least 1 AE	21.3% (10)	16.3% (8)	18.4% (9)	16.7% (8)

- No individual AE was reported by more than one subject in a treatment group
- No SAEs

